Icosavax to Participate in the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...

Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121 Against RSV and Initial Evidence for Revaccination Potential - In new data from Icosavax’s IVX-121 Phase 1b extension trial in older adults, GMTs against RSV through day 365 persisted at ~45-70% of the GMTs at day 28 (for 75 and 250 µg unadjuvanted dosages) - ...

Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older Adults - Phase 2 topline interim results expected in 1Q 2024 - - 6-month durability data for Phase 1 trial of IVX-A12 also expected in 1Q 2024 - SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) --...